tiprankstipranks
Trending News
More News >
RaQualia Pharma Inc. (JP:4579)
:4579
Japanese Market
Advertisement

RaQualia Pharma Inc. (4579) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4579

RaQualia Pharma Inc.

(4579)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
¥558.00
▲(6.90% Upside)
RaQualia Pharma Inc. faces significant financial challenges, with negative revenue growth and profitability issues being the most impactful factors. Technical analysis shows mixed signals, and valuation metrics are weak due to negative earnings. The absence of earnings call data and corporate events further limits the stock's appeal.

RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)

RaQualia Pharma Inc. Business Overview & Revenue Model

Company DescriptionRaQualia Pharma Inc. is a biopharmaceutical company focused on the development and commercialization of innovative drugs primarily in the fields of gastrointestinal and central nervous system disorders. The company operates within the pharmaceutical sector, leveraging its proprietary drug development platforms to create new therapeutic options. Its core products include novel compounds that target unmet medical needs, particularly in areas such as pain management and digestive health.
How the Company Makes MoneyRaQualia Pharma Inc. generates revenue through a combination of product sales, licensing agreements, and partnerships with larger pharmaceutical companies. The company markets its proprietary drugs directly or through collaborations, receiving royalties on sales from licensed products. Additionally, strategic partnerships and collaborations with research institutions and other biotech firms provide funding and resources for drug development, contributing to revenue through milestone payments and profit-sharing arrangements. The company's ability to innovate and bring new therapies to market is crucial for sustaining its earnings.

RaQualia Pharma Inc. Financial Statement Overview

Summary
RaQualia Pharma Inc. shows potential in financial health with strong cash flow management and a stable balance sheet. However, it faces challenges in achieving consistent profitability and revenue growth. The company needs to focus on converting strong gross margins into net profits while leveraging its robust equity position for future growth.
Income Statement
45
Neutral
RaQualia Pharma Inc. has shown a volatile revenue growth pattern with recent TTM revenue increasing by 10.19% from the previous annual report, but with a declining trend compared to earlier years. The company struggles with profitability as indicated by negative net profit margins and EBIT margins in the recent periods, primarily due to consistent net losses. While gross profit margins remain strong at around 74.96% in TTM, the company needs to focus on reducing operational losses to improve overall profitability.
Balance Sheet
55
Neutral
The balance sheet reveals a moderate financial structure with a debt-to-equity ratio of 0.61 in TTM, indicating manageable leverage. The equity ratio remains robust at 57.82%, reflecting a solid equity base relative to total assets. However, the recent reduction in stockholders' equity highlights potential risks. Despite these concerns, the company maintains healthy liquidity with substantial cash reserves, suggesting resilience against short-term financial stress.
Cash Flow
40
Negative
Cash flow analysis shows a promising trend with a strong operating cash flow to net income ratio of -0.69 in TTM, highlighting efficient cash generation relative to reported losses. The free cash flow has improved significantly, growing by 131.36% from the last annual report, indicating better cash management. However, the company needs to ensure sustainable operating cash flows to support long-term growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.23B3.11B1.90B2.92B2.78B1.11B
Gross Profit2.31B2.48B1.66B2.69B2.46B969.29M
EBITDA229.81M188.27M-111.80M1.00B1.02B-403.25M
Net Income-525.92M-495.03M-323.66M723.39M755.79M-606.99M
Balance Sheet
Total Assets9.94B9.66B6.87B6.26B5.23B4.25B
Cash, Cash Equivalents and Short-Term Investments3.62B3.34B3.76B3.93B2.66B2.11B
Total Debt3.20B3.45B367.72M222.34M39.07M45.52M
Total Liabilities3.65B4.08B752.00M760.67M446.19M240.11M
Stockholders Equity6.29B5.57B6.12B5.50B4.79B4.01B
Cash Flow
Free Cash Flow-46.84M84.24M-940.80M1.45B260.61M-445.56M
Operating Cash Flow65.77M180.94M-718.60M1.48B366.03M-289.21M
Investing Cash Flow-48.06M-3.67B-135.37M-47.65M-279.25M225.47M
Financing Cash Flow462.90M2.98B793.45M-29.56M-16.44M-6.96M

RaQualia Pharma Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price522.00
Price Trends
50DMA
570.36
Negative
100DMA
569.76
Negative
200DMA
483.73
Positive
Market Momentum
MACD
-6.68
Positive
RSI
38.23
Neutral
STOCH
19.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Negative. The current price of 522 is below the 20-day moving average (MA) of 570.25, below the 50-day MA of 570.36, and above the 200-day MA of 483.73, indicating a neutral trend. The MACD of -6.68 indicates Positive momentum. The RSI at 38.23 is Neutral, neither overbought nor oversold. The STOCH value of 19.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4579.

RaQualia Pharma Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
¥10.39B284.550.95%-13.81%-107.95%
53
Neutral
¥18.63B-9.04%2.12%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
¥16.58B206.4013.83%34.66%
47
Neutral
¥12.77B40.66%24.86%
47
Neutral
¥18.33B5.59%
46
Neutral
¥10.41B268.05%83.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4579
RaQualia Pharma Inc.
522.00
30.00
6.10%
JP:4588
Oncolys BioPharma, Inc.
700.00
79.00
12.72%
JP:4599
StemRIM Inc.
295.00
-81.00
-21.54%
JP:4880
CellSource Co., Ltd.
524.00
-731.69
-58.27%
JP:4888
STELLA PHARMA CORPORATION
306.00
-203.00
-39.88%
JP:4978
ReproCELL Inc.
175.00
61.00
53.51%

RaQualia Pharma Inc. Corporate Events

RaQualia Pharma Reports First Half 2025 Financial Results with Increased Sales
Aug 14, 2025

RaQualia Pharma Inc. reported its consolidated financial results for the first half of the fiscal year ending December 31, 2025. The company experienced an increase in net sales by 8.9% compared to the same period last year, although it still reported a net loss. The financial position showed an improvement in total assets and equity ratio, indicating a stronger balance sheet. Despite the losses, the company maintains its forecast for the fiscal year, suggesting confidence in its strategic direction.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 11, 2025